1 | INTRODUCTION

Chronic hepatitis C virus (HCV) is one of the world’s leading causes of liver cirrhosis and hepatocellular carcinoma with wider health impacts like cardiovascular disease, mental health issues and renal complications. HCV is a blood-borne virus that impacts around 71 million people globally and approximately 34,500 people in Scotland where it is transmitted most commonly through injection drug use.

While there is some emerging evidence that antibodies may be partially protective, there is no vaccine available, making prevention
TABLE 1 inclusion and exclusion criteria

| Inclusion Criteria | Exclusion Criteria |
|--------------------|--------------------|
| a. Any patient alive at any point from 1st January 2015 – 31st December 2019 AND | a. Any patient treated and cured prior to 1st January 2015 |
| b. In Tayside for longer than 2 months (including those in custody of Tayside HMP) AND | b. Any patient that died before 2015 |
| c. With at least one HCV infection (PCR positive, DBST positive or antibody positive with no subsequent negative PCR) | c. Any patient that spontaneous resolved before 2015 (Antibody positive, PCR Negative) |

Any patient diagnosed and treated before 2015 without a successful SVR, that was alive in Tayside between 2015 and 2019

Any patient in Tayside treated with DAAs starting in 2014 and ending in 2015
difficult and reinfections common in high-risk populations. The variable diagnosis-to-cure journeys, transient populations and possibility of reinfection present challenges to health services attempting to monitor and visualize the progression of their epidemic or the efficacy of pathways.

HCV was once treated with interferon-based regimens, which were lengthy and posed significant side effects, mediocre cure rates and poor compliance. Between 2013 and 2015, direct acting antivirals (DAAs) became the standard of care for many countries like Scotland, providing an easily administered oral option with over 95% efficacy across genotypes. With the introduction of DAAs, eradication of the disease has become possible and the World Health Organization (WHO) has set Elimination Goals for 2030 tasking each health system with evaluating their own epidemic and progress towards said targets. These include a 90% diagnosis rate, 80% treatment rate of those eligible, 90% reduction in incidence and 65% reduction in mortality. The WHO has highlighted priority actions for countries such as information gathering, prevention, national target setting and revising plans as necessary.

In order to monitor both the progression of an epidemic towards targets and utilize the metrics to make strategic healthcare provision decisions on the ground, data must be collected and communicated effectively. Insights about an infectious disease epidemic, like that of HCV, can be gained by analysing a health system’s cascade of care (CoC) which depicts how infected cases move through the steps of effective disease control in a continuum of services. CoC has been effectively used to identify gaps in HCV care, plan service delivery to intensify efforts in key areas, evaluate the progression of the epidemic and monitor health system effectiveness in order to improve the health and increase the treatment rates of those living with HCV.

While CoC is used around the globe, approaches to data coding, analysis and reporting vary. Hepatitis C specialist teams have debated the best ways to capture yearly snapshots of the current state of the epidemic, appreciate how the epidemic changes over time, emphasize the nuances at each stage of the cascade and compare how progress meets set targets. A standardized method would facilitate the comparison and knowledge exchange across time, settings, subpopulations and health systems.

In order to evaluate yearly snapshots of an epidemic, its cumulative evolution over time, nuance at each stage of the cascade and progression towards elimination targets, this paper proposes a novel, systematic way of codifying HCV cases along the proposed cascade of Care: Diagnosis, Treatment and Cure. It also evaluates the hepatitis C cascade of Care in Tayside, Scotland, to provide examples of insights gained from displaying data in this way.

2 | METHODOLOGY

2.1 | Data sources

NHS Tayside maintains records of all patients who have tested positive for hepatitis C RNA or antibodies since 1993, including those who are only temporarily in the region, those who spontaneously resolve the infection and have undetectable HCV RNA levels and those who have relocated from the region either temporarily or indefinitely. The current database holds demographic and clinical information of 3917 people over 18 years old.

In order to capture each patient’s HCV timeline, variables including PCR positive test dates, past medical history, DAA treatment start dates and statuses, cure dates, death dates and relocation history were collated from the local HCV database, NHS Tayside Clinical portal and Sunquest Integrated Clinical Environment (ICE) system, which reports patients’ laboratory results. Qualitative information regarding treatment status and relocation history was gathered from clinical letters recorded from the pharmacy service, harm-reduction service, Tayside Substance Misuse Service, and other health or social care services, where available. Caldicott Guardian approval was obtained to access patient data (ref: IGTCAL4762).

2.2 | Cohort selection

A cohort of individuals with active infections after the widespread introduction of DAAs in 2015 was identified. The inclusion and exclusion criteria are outlined in Table 1. For clarity, those that began treatment with DAAs in late 2014 and finished in 2015 were included as they were the early adopters of what would become standard care in 2015 (n = 9). Also, those treated with interferon after 2015 were included as they were part of a clinical trial and contributed to Tayside’s overall epidemic (n = 70); any subsequent infections and treatments with DAAs in these individuals were coded as usual. All HCV positive people that were prisoners for at least two months in Her Majesty’s Prison (HMP) in Perth were included as they fall under Tayside’s medical service provision, contribute to Tayside’s prevalence and potentially transmit to other Tayside residents for the duration of their stay. Those that moved in and out of Tayside more than two times over the five years were not considered residents in Tayside and were, therefore, excluded from the
analysis. All people that had been treated before 2015 and had not had confirmed SVRs and people with a positive antibody test but no subsequent PCR data have been included as they may still have active infections. Reinfections in the same person, whether in the same year or in subsequent years, are coded as separate infections, treatments and cures.

Figure 1 outlines the cohort selection process based on inclusion/exclusion criteria. 1476 people that were alive, in Tayside, and had at least one active hepatitis C infection since 2015 were ultimately included in the study cohort.

2.3 Coding framework

Using the variables to identify important statuses in the diagnosis-to-cure journey, a framework was created to codify each patient’s Diagnosis, Treatment and Cure status at each point in time (Table 2). The coding framework was then used to codify each of the 1476 patients in our data set each year from 2015 to 2019 to produce an example stacked clustered bar chart. Details of the methodological nuances and special considerations that are important in replicating this method are detailed in Table 3.

3 RESULTS

The coding framework was used on the Tayside data set to produce an example stacked clustered bar chart (Figure) with the supporting raw data (Figure 2B).

Similarly to previous methods used, this method of displaying a cascade of care communicates the basic disease control stages: Diagnosis, Treatment and Cure. It provides a cumulative overview of the epidemic’s progression during a period of time while also allowing for yearly comparison of the disease control stages.

Conversion rates, which indicate the percentage of people per year who move from diagnosis to treatment or cure, help to note overall progression towards defined targets and identify specific periods of success or struggle in the elimination efforts. In Tayside, diagnosis-to-treatment rates went from 19% (2015) to 50% (2019) and diagnosis-to-cure rates went from 18% (2015) to 49% (2019). Both diagnosis-to-treatment and diagnosis-to-cure rates saw the most significant rise from 2016 to 2017.

The method also provides a variety of nuance and distinction within each stage by offering 12 sub-stages of the cascade instead of the usual 3 (Diagnosis, Treatment and Cure). All of the following numerical figures for Tayside are expressed as averages from 2015 to 2019 unless otherwise specified.

Firstly, those who are unsuitable for treatment for clinical reasons will not progress through the cascade and are important to distinguish. Patients unsuitable for treatment include those that are palliating with advanced disease from other organs or those in which DAAs are contraindicated. In Tayside, 2% of diagnosed patients fall in this category.

Secondly, previously diagnosed patients and newly diagnosed patients are stratified both at the Diagnosis and Treatment stages. This is useful in clarifying the portion of patients with new diagnoses each year and to identify barriers in progressing new or previously diagnosed patients from Diagnosis to Treatment. In Tayside, the number of newly diagnosed patients is broadly similar year-on-year while the number of previously diagnosed patients decreases. Each year, 34% of newly diagnosed patients and 29% of previously diagnosed patients enter treatment. Newly diagnosed patients progressing to treatment increased from 12% (2015) to 60% (2019), and previously diagnosed patients progressing to treatment increased from 19% (2015) to 36% (2019).

Thirdly, unsuccessful and incomplete treatments are evidenced to clarify whether efforts need to be put into improving treatment types or increasing treatment compliance, respectively. In Tayside, 3% of treatment courses are unsuccessful and 6% of courses are incomplete. It is interesting to note that 23 people who did not complete treatment still achieved SVR. Of these, 1 patient partially completed a 24-week course of interferon [8 weeks], 8 partially completed an 8-week course of DAAs (Range = 2-7 weeks, Median = 4.5 weeks), 13 partially completed a 12-week course of DAAs (Range = 1-11 weeks, Median = 6 weeks), and 1 was unclear.

Fourthly, the portion of patients who have completed treatment but do not have a confirmed SVR is shown to provide information on patients that require follow-up. In Tayside, the service is still attempting to follow-up 5% of patients to confirm their post-treatment SVR status.

Lastly, deaths and patients that relocate are shown at each stage of the cascade. In Tayside, 4% of patients died and 2% moved each year.
4 | DISCUSSION

The coding framework suggested in this paper could be applied across healthcare systems to add nuance to stages of the cascade and to standardize definitions. This could facilitate the comparison across settings and systems, providing a potential reporting method the WHO might suggest to countries tracking their epidemics. An example of how the framework can be practically applied to any system’s HCV data can be found in Appendix 1.

| Category      | Code                          | Definition                                                                                                                                 |
|---------------|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Diagnosis     | Previous Diagnosis           | Patients with an active HCV infection, first diagnosed before the given year that has not been treated successfully or spontaneously resolved |
|               | New Diagnosis                 | Patients with an active HCV infection, first diagnosed at any point in the given year                                                     |
|               | Can't Treat                   | Patients with an active HCV infection first diagnosed at any point in the given year that are unsuitable for treatment, usually for palliative reasons |
|               | Moved                         | Patients with an active HCV infection first diagnosed at any point in the given year or beforehand that has moved before progressing to treatment |
|               | Dead                          | Patients with an active HCV infection first diagnosed at any point in the given year or beforehand that has died before progressing to treatment |
| Treatment     | Treatment - Previous Diagnosis| Treatment of a patient with an active HCV infection, first diagnosed before the given year that has not been treated successfully or spontaneously resolved |
|               | Treatment - New Diagnosis     | Treatment of a patient with an active HCV infection, first diagnosed at any point in the given year                                         |
|               | Treatment Unsuccessful        | Unsuccessful treatment of a patient with an active HCV infection first diagnosed at any point in the given year or beforehand                   |
|               | Treatment Incomplete          | Incomplete treatment of a patient with an active HCV infection first diagnosed at any point in the given year or beforehand                     |
|               | Moved                         | Patients with an active HCV infection treated at any point in the given year that has moved before progressing to cure                       |
|               | Dead                          | Patients with an active HCV infection treated at any point in the given year that has died before progressing to cure                         |
| Cure          | Cure                          | Patients who have achieved a clear Sustained Virologic Response (SVR), defined by HCV RNA below the lower level of detection, 12 weeks post-treatment; assigned to the year the treatment started |
|               | Spontaneously Resolved        | Patients who have a negative PCR test after previously having a positive PCR test but have not accessed treatment; assigned to the year of the negative test. |
|               | Unknown SVR                   | Patients who have completed treatment, but their SVR status has not been confirmed; assigned to the year the treatment started                |
|               | Moved                         | Patients who have moved after completing treatment but before confirming they have achieved SVR; assigned to the year the treatment started  |
|               | Dead                          | Patients who have died after completing treatment but before confirming they have achieved SVR; assigned to the year the treatment started  |
Having used the method to analyse the Tayside data, it was evident that the area has been successful at both managing and tracking the local HCV epidemic. This may be attributed to their quick transition from interferon-based treatments to DAAs in 2015 and universal access to treatment provided for virtually all those infected. Tayside has utilized innovative testing and treatment pathways, some of which are located within community pharmacies and harm-reduction centres, to widen access to services at each stage of the cascade.13-15 As in many settings, there are continuing challenges in providing services to those that are hardest to reach, such as those that frequently relocate or those that may not regularly engage with healthcare services.

Beyond Tayside, the method proposed in this paper can be implemented with basic spreadsheet tools that have pivot table and graphing functions. While the method, as described here, has been created to meet Tayside’s needs using their rich data collection and

### Table 3: Methodological nuances and special considerations

| Diagnosis | Reinfections, whether in the same year or in subsequent years, are coded separately as individual infections. Patients with a positive DBST and negative PCR taken on the same day are considered negative as PCR is a more specific test. The small number of patients that are diagnosed in Tayside, move away and return to Tayside at a later date with an active infection are first coded as "New Diagnosis" and upon return coded as "Diagnosis Carrier." |
| Treatment | Though rare, multiple treatments for the same infection, whether in the same year or in subsequent years, are coded separately as individual treatments. Patients coded as "Treatment Unsuccessful" or "Treatment Incomplete" without a confirmed SVR for one year are coded as "Previous Diagnosis" for the successive year as they had not cleared the virus and are still pending a successful treatment. Though it is difficult to distinguish between a spontaneous resolution + reinfection or if the treatment was unsuccessful without genotyping each sample, patients who have a continually high viral load who have completed treatment without an SVR are coded as "Treatment Unsuccessful." Some samples are genotyped and if there is a distinct change in genotype, the cases are coded as two separate infections. Diagnosis-to-treatment rates are calculated by all patients in a specific year that are at the treatment stage (["Treatment"] – ["Previous Diagnosis"] + ["Treatment"] – ["New Diagnosis"] + ["Treatment Unsuccessful"] + ["Treatment Incomplete"] + ["Treatment"] – ["Moved"] + ["Treatment"] – ["Dead"]) divided by ["Previous Diagnosis"] + ["New Diagnosis"] for that same year. New Diagnosis Treatment and Previous Diagnosis Treatment rates are calculated by dividing ["Treatment"] – ["New Diagnosis"] by ["New Diagnosis"] and ["Treatment"] – ["Previous Diagnosis"] by ["Previous Diagnosis"], respectively. Unsuccessful and Incomplete Treatment proportions are calculated by dividing ["Treatment Unsuccessful"] or ["Treatment Incomplete"] by ["Treatment"] – ["New Diagnosis"] + ["Treatment Unsuccessful"] + ["Treatment Incomplete"].

| Cure | Cured cases are coded in the year that they started treatment. Since very high real world SVR rates have been observed in patients who completed treatment, patients with an End of Treatment Negative result are coded as achieving "Cure." Patients who have completed treatment but have not returned for SVR bloods are coded as "Unknown SVR" each year until they either have SVR bloods or a new PCR positive test, at which point they will again be coded as "Diagnosis." Patients that do not complete treatment but achieve SVR are coded as "Treatment Incomplete" and "Cure" Patients coded as "Dead" at the cured stage have completed treatment and are awaiting SVR bloods when they pass. Diagnosis-to-cure rates are calculated by ["Cure"] + ["Unknown SVR"] + ["Cure"] – ["Moved"] + ["Cure"] – ["Dead"] from a specific year divided by ["Previous Diagnosis"] + ["New Diagnosis"] for that same year. Unknown SVR rates are calculated by ["Unknown SVR"] divided by ["Cure"] + ["Unknown SVR"].

| General | Deceased patients are coded as "Dead" within the last stage of the cascade that they completed in the year that they passed. Patients that move away from the region are coded as "Moved" within the last stage of the cascade that they moved. |
storage processes, the method is malleable and could be adapted to other settings. Areas with less robust data can combine or remove codes to produce a more simplified version of the CoC, though this may impact the nuance and utility of the information. Similarly, new codes, such as reinfections, could be developed if useful to that local setting. Adding codes provides more helpful detail; however, it also increases the burden of data collection, adds complexity to the chart and loses the standardization of definitions. Further research is warranted to understand how this method might be applied in various healthcare settings with different diagnosis pathways, treatment services and levels of data keeping.

In conclusion, overall, this project proposes a novel way of codifying and displaying cascades of care data that relays yearly comparisons of an epidemic, overall progression over time, nuance within disease control stages and progress towards elimination targets. The coding framework can be used to standardize definitions across settings and the stacked clustered bar chart improves service evaluation to offer insights to healthcare planners who want a comprehensive understanding of what fuels or hinders a local cascade. More broadly, it can facilitate knowledge exchange across global health systems and offer a new way to track global infectious epidemics.
ACKNOWLEDGEMENTS
Ann Eriksen, Jan Tait, Shirley Cleary, Maya Prakash, Linda Johnston, Farsana Ahmad, Brian Stephens, Eilidh Fergus and the teams at the test and treat sites within Tayside. Initial data analysis funding was provided to Cassandra Baiano by the Dundee Clinical Academic Track.

CONFLICT OF INTEREST
CB, MC, EMR: None; JFD: honoraria for lectures and research grants from Janssen-Cilag, Roche, Merck Sharp & Dohme, AbbVie, Bristol-Myers Squibb and Gilead Sciences outside the submitted work.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Cassandra X. Baiano https://orcid.org/0000-0003-3562-3059

REFERENCES
1. Eliminating Hepatitis C in Scotland: A Call to Action. The Hepatitis C Trust; 2018. Accessed August 8, 2019. http://www.hepctrust.org.uk/sites/default/files/Eliminating%20Hepatitis%20C%20FINAL.pdf
2. World Health Organization, World Health Organization, Global Hepatitis Programme. Global Hepatitis Report, 2017:. 2017. Accessed August 8, 2019. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1
3. Abdel-Hakeem MS, Shoukry NH. Protective immunity against hepatitis C: many shades of gray. Front Immunol. 2014;5:274. https://doi.org/10.3389/fimmu.2014.00274.
4. Asselah T, Marcellin P, Schinazi RF. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver Int Off J Int Assoc Study Liver. 2018;38(Suppl 1):7–13. https://doi.org/10.1111/liv.13673.
5. Combating Hepatitis B and C to Reach Elimination by 2030. World Health Organization; 2016:20. Accessed August 6, 2019. https://apps.who.int/iris/bitstream/handle/10665/206453/WHO_HIV_2016.04_eng.pdf?sequence=1
6. Global Health Sector Strategies on Viral Hepatitis 2016-2021. World Health Organization; 2016:56. Accessed August 6, 2019. https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1
7. Socias ME, Volkow N, Wood E. Adopting the “Cascade of Care” framework: an opportunity to close the implementation gap in care? Addict Abingdon Engl. 2016;111(12):2079-2081. https://doi.org/10.1111/add.13479.
8. Yehia BR, Schranz AJ, Umscheid CA, Lo RV. The treatment cascade for chronic hepatitis c virus infection in the united states: a systematic review and meta-analysis. PLoS One. 2014;9(7): https://doi.org/10.1371/journal.pone.0101554
9. Thomas DL. State of the hepatitis C virus care cascade. Clin Liver Dis. 2020;16(1):8-11. https://doi.org/10.1002/clid.915.
10. Maier MM, Ross DB, Chartier M, Belperio PS, Backus LI. Cascade of care for hepatitis C virus infection within the US veterans administration. Am J Public Health. 2016;106(2):353–358. https://doi.org/10.2105/AJPH.2015.302927.
11. Carvalho-Louro DM, Soares EB, Trevizoli JE, et al. Hepatitis C screening, diagnosis, and cascade of care among people aged > 40 years in Brasilia, Brazil. BMC Infect Dis. 2020;20(1):114. https://doi.org/10.1186/s12879-020-4809-2.
12. Safreed-Harmon K, Blach S, Aleman S, et al. The consensus hepatitis C cascade of care: standardized reporting to monitor progress toward elimination. Clin Infect Dis Off Publ Infect Dis Soc Am. 2019;69(12):2218–2227. https://doi.org/10.1093/cid/ciz714.
13. Radley A, de Bruin M, Ingls SK, et al. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. Lancet Gastroenterol Hepatol. 2020;5(9):809–818. https://doi.org/10.1016/S2468-1253(20)30120-5.
14. Inglis SK, Beer LJ, Byrne C, et al. Randomised controlled trial conducted in injecting equipment provision sites to compare the effectiveness of different hepatitis C treatment regimens in people who inject drugs: A Direct obserVed therApy versus fortNightly CollEction study for HCV treatment--ADVANCE HCV protocol study. BMJ Open. 2019;9(8):e029516. https://doi.org/10.1136/bmjopen-2019-029516.
15. Byrne C, Radley A, Inglis SK, et al. Reaching mEthadone users Attending Community pHarmacies with HCV: an international cluster randomised controlled trial protocol (REACH HCV). BMJ Open. 2020;10(8):e036501. https://doi.org/10.1136/bmjopen-2019-036501.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Baiano CX, Caven M, Robinson EM, Dillon JF. Evaluating and communicating hepatitis C cascades of care data in Tayside, Scotland: A journey towards elimination. J Viral Hepat. 2021;28:909–915. https://doi.org/10.1111/jvh.13505